CTB-p210 fusion protein vaccine(Abcentra)

N/A

Report date: 2025/01/26 18:20:57

Base Information

Drug NameCTB-p210 fusion protein vaccine(Abcentra)
Drug Alias Nameatherosclerosis vaccine (CardioVax/Lund University Hospital)atherosclerosis vaccine (CardioVax)atherosclerosis vaccine (CardioVax)atherosclerosis vaccine (Abcentra)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionApolipoprotein B-100 modulators
TargetsApolipoprotein B-100
Therapy Area/IndicationsAtherosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAbcentra LLC
China Registration ClassN/A

Develop Information

Active CompaniesAbcentra LLCSkane University Hospital
Inactive CompaniesN/A
Active IndicationsAtherosclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A